Dasatinib inhibits mammary tumour development in a genetically engineered mouse model
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 230, Issue 4, Pages 430-440
Publisher
Wiley
Online
2013-04-25
DOI
10.1002/path.4202
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SRC: A Century of Science Brought to the Clinic
- (2015) Alexey Aleshin et al. NEOPLASIA
- Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
- (2012) Antonio Garcia-Gomez et al. PLoS One
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
- (2011) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence
- (2011) K. Han et al. CLINICAL ONCOLOGY
- Clinicopathological significance of Y416Src and Y527Src expression in breast cancer
- (2011) N. Kanomata et al. JOURNAL OF CLINICAL PATHOLOGY
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis
- (2011) R. Marcotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
- (2010) Yi Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Significance of ER–Src axis in hormonal therapy resistance
- (2010) Sreeram Vallabhaneni et al. BREAST CANCER RESEARCH AND TREATMENT
- Quantitative In vivo Imaging of the Effects of Inhibiting Integrin Signaling via Src and FAK on Cancer Cell Movement: Effects on E-cadherin Dynamics
- (2010) M. Canel et al. CANCER RESEARCH
- Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
- (2010) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- (2010) Jennifer P. Morton et al. GASTROENTEROLOGY
- Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy
- (2010) S. Moulder et al. MOLECULAR CANCER THERAPEUTICS
- Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
- (2010) Y-C Lee et al. ONCOGENE
- Control of mammary tumor differentiation by SKI-606 (bosutinib)
- (2010) L Hebbard et al. ONCOGENE
- Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients?
- (2009) Beatrix Elsberger et al. AMERICAN JOURNAL OF PATHOLOGY
- Dasatinib synergizes with doxorubicin to block growth, migration and invasion of breast cancer cells
- (2009) C S Pichot et al. BRITISH JOURNAL OF CANCER
- Real-time Study of E-Cadherin and Membrane Dynamics in Living Animals: Implications for Disease Modeling and Drug Development
- (2009) A. Serrels et al. CANCER RESEARCH
- Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors
- (2009) Y. Chen et al. CLINICAL CANCER RESEARCH
- Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
- (2009) O. Tatarov et al. CLINICAL CANCER RESEARCH
- c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential
- (2009) R. Marcotte et al. MOLECULAR AND CELLULAR BIOLOGY
- Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
- (2008) Feng (Roger) Luo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis
- (2008) N. Dourdin et al. CANCER RESEARCH
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model
- (2008) Bryan Serrels et al. CARCINOGENESIS
- Src and focal adhesion kinase as therapeutic targets in cancer
- (2008) Valerie G Brunton et al. CURRENT OPINION IN PHARMACOLOGY
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
- (2008) R. Buettner et al. MOLECULAR CANCER RESEARCH
- Tracing pathway activities with kinase inhibitors and reverse phase protein arrays
- (2008) Jan van Oostrum et al. Proteomics Clinical Applications
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started